These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

756 related items for PubMed ID: 25987623

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Evaluation of Telavancin Alone and Combined with Ceftaroline or Rifampin against Methicillin-Resistant Staphylococcus aureus in an In Vitro Biofilm Model.
    Jahanbakhsh S, Singh NB, Yim J, Rose WE, Rybak MJ.
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29784849
    [Abstract] [Full Text] [Related]

  • 6. Impact of Daptomycin Dose Exposure Alone or in Combination with β-Lactams or Rifampin against Vancomycin-Resistant Enterococci in an In Vitro Biofilm Model.
    Jahanbakhsh S, Singh NB, Yim J, Kebriaei R, Smith JR, Lev K, Tran TT, Rose WE, Arias CA, Rybak MJ.
    Antimicrob Agents Chemother; 2020 Apr 21; 64(5):. PubMed ID: 32094136
    [Abstract] [Full Text] [Related]

  • 7. Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.
    Parra-Ruiz J, Vidaillac C, Rose WE, Rybak MJ.
    Antimicrob Agents Chemother; 2010 Oct 21; 54(10):4329-34. PubMed ID: 20696880
    [Abstract] [Full Text] [Related]

  • 8. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model.
    Werth BJ, Sakoulas G, Rose WE, Pogliano J, Tewhey R, Rybak MJ.
    Antimicrob Agents Chemother; 2013 Jan 21; 57(1):66-73. PubMed ID: 23070161
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Phage-antibiotic synergy against daptomycin-nonsusceptible MRSA in an ex vivo simulated endocardial pharmacokinetic/pharmacodynamic model.
    Kunz Coyne AJ, Bleick C, Stamper K, Kebriaei R, Bayer AS, Lehman SM, Rybak MJ.
    Antimicrob Agents Chemother; 2024 Apr 03; 68(4):e0138823. PubMed ID: 38376187
    [Abstract] [Full Text] [Related]

  • 11. In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure.
    Bhalodi AA, Hagihara M, Nicolau DP, Kuti JL.
    Antimicrob Agents Chemother; 2014 Apr 03; 58(2):672-7. PubMed ID: 24217694
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of Staphylococcus aureus in a Simulated Pharmacodynamic/Pharmacokinetic Model.
    Kebriaei R, Rice SA, Stamper KC, Rybak MJ.
    Antimicrob Agents Chemother; 2019 Apr 03; 63(4):. PubMed ID: 30670436
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
    Leonard SN, Rybak MJ.
    J Antimicrob Chemother; 2009 Jan 03; 63(1):155-60. PubMed ID: 18984644
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.